Molecular Mechanisms of Antibiotic Resistance inHelicobacter pylori
Kathleen R. Jones1, Jeong-Heon Cha2, D. Scott Merrell1*
1. Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd. , Bethesda, MD 20814
2.Department of Oral Biology, Oral Science Research Center, BK21 undertaking, Yonsei University College of Dentistry, Seoul, Korea
* Corresponding writer, Mailing reference: Department of Microbiology and Immunology,
Uniformed Services University of the Heath Sciences, 4301 Jones Bridge Rd. , Bethesda, MD 20814. Telephone: ( 301 ) 295-1584. Facsimile: ( 301 ) 295-3773.
The ability of clinicians to pay an effectual war against many bacterial infections is progressively being hampered by skyrocketing rates of antibiotic opposition. Indeed, antibiotic opposition is a important job for intervention of diseases caused by virtually all known infective bacteriums. The stomachic pathogenHelicobacter pyloriis no exclusion to this regulation. With more than 50 % of the universe ‘s population infected,H. pyloriexacts a enormous medical load and represents an interesting paradigm for malignant neoplastic disease development ; it is the lone bacteria that is presently recognized as a carcinogen. It is now steadfastly established thatH. pyloriinfection is associated with diseases such as gastritis, peptic and duodenal ulceration and two signifiers of stomachic malignant neoplastic disease, stomachic glandular cancer and mucosa-associated lymphoid tissue ( MALT ) lymphoma. With such a big per centum of the population infected, increasing rates of antibiotic opposition are peculiarly annoying for a intervention government that is already reasonably complicated ; intervention consists of two antibiotics and a proton pump inhibitor. To day of the month, opposition has been found to all primary and secondary lines of antibiotic intervention every bit good as to drugs used for deliverance therapy.
The war between antibiotics and bacteriums
The cognition that bacteriums were susceptible to antibiotics had its generation in 1877 with the first study by Pasteur and Joubert that a bacteria produced a toxic substance that killed other bacteriums ( cited in [ 1 ] ) . Fifty-two old ages subsequently, penicillin was identified in 1929 as an antimicrobic by Fleming [ 2 ] . After it was shown that penicillin was able to forestall a deadly infection of streptococci in mice [ 3 ] and to handle human disease [ 4, 5 ] , it was thought that antibiotics would easy extinguish infective disease. However, to everyone ‘s surprise, bacteriums are strategic combatants, and have adapted to go immune to a battalion of antibiotics used to handle infection. Because of this, it is no hyperbole to state that, on some foreparts, bacteriums are on the brink of winning the war.
Broadly defined, antibiotics are either natural or man-made merchandises that kill ( bacteriocidal ) or inhibit growing ( bacteriostatic ) of bacterium. Antibiotics must be selectively toxic for the bug, and current drug categories target four cardinal facets of bacterial growing and physiology. The marks include bacterial cell wall synthesis, foliate coenzyme synthesis, protein synthesis, and nucleic acid ( DNA or RNA ) synthesis [ 6 ] . Bacterial antibiotic opposition mechanisms can similarily be broken into five major categories. These include change of the antibiotic mark, enzymatic devastation of the antibiotic, enzymatic alteration of the antibiotic, reduced permeableness of the antibiotic, and increased outflow of the antibiotic from the bacterial cell ( Table 1 ) [ 6 ] .
Introduction of the enemy:Helicobacter pylori
Helicobacter pyloriwas foremost isolated from patients enduring from chronic gastritis in 1982 [ 7 ] .H. pyloriis a Gram-negative, coiling shaped bacteria that colonizes the arguably inhospitable niche of the tummy, and persists for the life-time of the host, if untreated [ 8 ] . Additionally,H. pyloricauses a broad scope of diseases. This being is associated with gastritis, 90 % of all duodenal ulcers, 75 % of all stomachic ulcers [ 9 ] , and two signifiers of tummy malignant neoplastic disease, glandular cancer and MALT lymphoma [ 9-12 ] . Though infection rates show broad geographic distribution, this strategic bacteria inveterate colonizes over 50 % of the universe ‘s population [ 13 ] . The high incidence ofH. pyloriinfection probably contributes to the fact that stomachic malignant neoplastic disease mortality ranks 2nd among all malignant neoplastic disease deceases worldwide [ 14 ] . Due to the causal relationship betweenH. pyloriand stomachic malignances, the World Health Organization classifiedH. pylorias a Class I carcinogen in 1994 [ 15 ] . Currently,H. pyloriis the lone bacteria to hold achieved this parlous differentiation.
During the comparatively short period of clip that we have known aboutH. pylori,at that place have been many different intervention regimens developed ( reviewed in [ 16 ] . In fact, in 1994 there was a consensus from the National Institute of Health [ 17 ] , followed two old ages subsequently by the Maastricht Consensus from the European Helicobacter Study Group [ 18 ] , which established intervention recommendations to handleH. pyloriinfection. Given the addition in incidence of antibiotic opposition, the Maastricht Consensus study was updated in 2000 and once more in 2005 to increase the effectivity of intervention regimens againstH. pylori[ 19, 20 ] .
The current recommendation for first line therapy in locations where clarithromycin opposition is low, is a protein pump inhibitor, clarithromycin, and either Flagyl ( first pick ) or Amoxil ( 2nd pick ) for 14 yearss [ 20 ] . Additionally, these ternary therapy regimens can be supplemented by the add-on of Bi in geographical countries where antibiotic opposition is high, though this combination is typically recommended as a 2nd line therapy [ 20 ] . Furthermore, since Bi is non available in many states, a combination of a proton pump inhibitor, Flagyl, and either Amoxil or Achromycin is sometimes recommended [ 20 ] .
Primary and secondary therapies are non ever successful at eliminatingH. pylori; therefore, there are many alternate drugs that are proposed for deliverance therapy. These include fluoroquinolones ( such as levofloxacin ) , rifamycins ( such as rifabutin and rifampicin ) , nitrofurans ( such as furazolidone ) and other members ( such as doxycline ) within households that are already used to handleH. pyloriinfection ( reviewed in [ 16, 21 ] . Of note, opposition has been found to all utilised primary and secondary antibiotics, every bit good as, to many of the disinfectants used for deliverance therapy. This fact suggests that therapy success rates will go on to worsen, and indicates that a elaborate apprehension of antibiotic opposition mechanisms may ease development of fresh therapeutics. As such, the molecular mechanisms ofH. pyloriantimicrobic opposition is discussed in item in this reappraisal ( Table 2 and Figure 1 ) .
First Line Therapy and Resistance:
Macrolides ( chiefly clarithromycin )
Clarithromycin is one of the first line therapy antibiotics used againstH. pyloriand is portion of a category of wide spectrum antibiotics called macrolides [ 20 ] . Macrolides map to forestall protein interlingual rendition. Specifically, these antibiotics interact with the bacterial ribosome and advance the premature release of peptidyl-tRNA from the acceptor site [ 22, 23 ] .
Macrolide resistantH. pyloristrains have been shown to be selected for during the class of intervention [ 24 ] . Furthermore, clarithromycin opposition has been pinpointed to nucleotide mutants, the bulk of which are individual nucleotide mutants, in one of the two macrolide adhering spheres of the 23S rRNA [ 25, 26 ] . Most important mutants are contained in Domain V of the 23S rRNA. In fact, this mechanism of clarithromycin opposition inH. pyloriwas first described in 1996 by Versalovicet Al.Since the terminology for these mutants is confounding due to fluctuation in the length of the 23S rRNA cistron among strains, for this reappraisal we will use the terminology for the 23S rRNA cistron published by Tayloret Al.[ 27 ] . At first, individual nucleotide permutations of an A to guanine at nucleotide places 2142 ( A2142G ) and 2143 ( A2143G ) , of the 23S rRNA were discovered [ 22 ] . Subsequently these same mutants were found in several other clarithromycin immune strains [ 22, 24, 27-32 ] . Extra grounds that mutants within this sphere are of import for macrolide reistance inH. pyloricame with the find that a transversion of an A to cytosine at place 2142 ( A2142C ) besides conferred clarithromycin opposition [ 33 ] . In some surveies every bit many as 91.4 % of clarithromycin immune strains contain the A2142G or the A2143G mutant [ 30 ] . Furthermore, these are the prevailing mutants found in Brazil [ 34 ] , France [ 35 ] , and Spain [ 36 ] .
Other mutants within sphere V of the 23S rRNA that have been identified to confabulate macrolide opposition include T2182C [ 37 ] , A2144T [ 38 ] , G2223A, C2244T, and T2288C [ 39 ] , though the ability of the T2182C mutant to confabulate macrolide opposition remains in inquiry, due to the fact that this mutant has been found in both immune and sensitive strains [ 40 ] . The dual mutant of A2115G and G2141A has besides been demonstrated to confabulate opposition [ 29, 41 ] .
Other of import clarithromycin opposition mutants lay outside of sphere V of the 23S rRNA. One such mutant, T2717C, consequences in low degree clarithromycin opposition [ 42 ] . Additionally, other clarithromycin resistantH. pyloristrains contain no mutants in the 23S rRNA [ 28, 42 ] . Though the exact mechanism remains vague, this fact indicates another agency of obtaining macrolide opposition. In other bacteriums, macrolide opposition can happen through methylation of a specific A on the 23S rRNA [ 25, 43, 44 ] . This is achieved through the presence of rRNA methylases, termedermcistrons ( erythromycin opposition methylase ) [ 43 ] . Despite the presence of clarithromycin opposition that is non associated with mutants of the 23S rRNA, scientists have failed to clone a individual Erythrocin opposition determiner from anyH. pyloriimmune isolate tested, and have failed to happen cistrons with homology to any antecedently reportedermcistrons [ 29 ] . This has left the nature of this opposition in inquiry. Interestingly,H. pylorihas the ability to take a different macrolide, Erythrocin, via the HefABC efflux pump ; nevertheless,H. pylorican non efflux clarithromycin through this pump [ 45 ] . Based on the surveies described above, it is clear that continued intervention ofH. pyloriwith clarithromycin will probably take to increasing rates of opposition, and may take to resistance to multiple macrolides due to cross-resistance [ 29 ] .
Beta-lactams ( Amoxil )
?-lactams are one of the best arms clinicians have againstH. pylori. The ?-lactam antibiotics are subdivided into 5 groups. These include penicillins, Mefoxins, carbapenems, monobactams, and clavams [ 6 ] . All ?-lactam antibiotics inhibit synthesis of the pepitoglycan bed of the bacterial cell wall. They do so by aiming penicillin binding proteins ( PBPs ) on the cytoplasmatic membrane [ 46 ] . These PBPs are enzymes that carry out carboxypeptidation and transpeptidation, which are the terminal stairss of peptidoglycan biogenesis [ 46-48 ] . Broadly speech production, in other bacteriums opposition to ?-lactams arises by reduced membrane permeableness of the drugs, increased outflow of the drug from the bacterial cell, alteration of the PBPs that diminish the affinity of the drug for the protein, and the presence of ?-lactamases that inactivate the antibiotic by hydrolysing its ring construction [ 6 ] .
Amoxicillin is a semi-synthetic penicillin that is presently the lone ?-lactam used to handleH. pyloriinfection. While initial intervention with Amoxil suggested that it was really effectual, amoxicillin opposition was documented in 1998, when the Hardenberg strain was isolated in Holland from an 82 twelvemonth old dyspeptic patient [ 49 ] . Currently, amoxicillin opposition rates vary from every bit low as 0 % to every bit high as 59 % [ 50-53 ] .
H. pyloricontains nine putative penicillin adhering proteins [ 54-56 ] . Of these, mutants of PBP1 [ 57-62 ] and PBP4 ( besides known as PBPD ) [ 54, 55 ] have been shown to impact amoxicillin opposition. In footings of PBP4, a reduced sum of this protein was demonstrated to confabulate low degree opposition to amoxicillin [ 55 ] . In fact, other immune strains were confirmed to hold no noticeable PBP4 [ 54, 55 ] .
In contrast, aminic acid mutants in PBP1 can ensue in opposition due to reduced affinity for Amoxil [ 57 ] . Surveies have shown that most aminic acid permutations that result in opposition occur in the carboxy end point of PBP1 in the penicillin adhering sphere [ 63 ] . For case, PBP1 from the Hardenberg strain contains a individual amino acerb permutation of serine to arginine at place 414 ( Ser414Arg ) [ 58, 63 ] . Interestingly, Kwonet Al.deduced that ?-lactam opposition was acquired with multidrug opposition, and that 10 different amino acid substations in the PBP1 pencillin adhering sphere could confabulate opposition: Glu406Ala, Ser417Thr, Met515Ile, Asp535Asn, Ser543Arg, Thr556Ser, Asn562Tyr, Lys648Gln, Arg649Lys, and Arg656Pro [ 59 ] . Two of the antecedently described aminic acerb mutants ( Thr556Ser and Asn562Tyr ) were subsequently confirmed, and extra amino acid mutants confabulating opposition were identified ; Ala369Thr, Val374Leu, Leu423Phe, Thr593Ala, and Gly595Ser [ 63 ] . Additionally, an INs vitrosurvey found that Thr438Met mutant is sufficient to do opposition [ 60 ] .
In add-on to decreased Amoxil adhering [ 57 ] , opposition can besides ensue from mutants that decrease membrane permeableness of the drug [ 47, 59, 61 ] . Mutants in two different outer membrane proteins have been proven to be sufficient to do amoxicillin opposition [ 60 ] . These mutants include mutants of aminic acids 116-201 ofhopBor a stop codon at amino acid 211 ofhopC[ 60 ] .
Nitroimidazoles, chiefly Flagyl:
Nitroimidazoles are synthesized as inactive prodrugs and necessitate decrease inside the bacteriums by specific non-human reductases to go active [ 64, 65 ] . In their active signifiers, nitroimidazoles produce toxic intermediates that consequence in DNA harm that kills the bacterium [ 64 ] . Metronidazole is a nitromidazole that was expeditiously used to handleH. pyloriinfection. However,H. pylorihas adapted to be able to strategically get away the effectivity of metronidazole intervention. Metronidazole opposition rates vary from 29-52 % [ 66, 67 ] in some parts, and are every bit high as 100 % in certain topographic points [ 68 ] .
The mechanism for metronidazole opposition inH. pyloriis likely the most studied and most controversial subject refering antibiotic opposition in theH. pylorifield. Early surveies showed that immune strains accumulated Flagyl at a slower rate and to a lesser extent than sensitive strains, proposing a function for transporters or efflux systems in opposition [ 69 ] . Other work suggested that mutants inrecAmight be responsible for opposition [ 70 ] , but subsequently surveies found no grounds that mutants inrecAlead to metronidazole opposition [ 71 ] .
The first existent discovery in understanding metronidozale opposition came with the find that immune bacteriums cut down other 5-nitroimidazole compounds more easy than sensitive strains [ 72 ] . This indicated that opposition is a merchandise of deficiency of decrease of the prodrugs [ 72 ] . Goodwinet Al.showed that Flagyl ‘s toxicity depends on its decrease by the oxygen-insensitive, nicotinamide A dinucleotide phosphate ( NADPH ) nitroreductase (rdxA) , and that opposition arises from mutants that inactivaterdxA [ 73 ] . Specifically, a nonsensical mutant caused the shortness of 14 amino acids, and other point mutants ( both bunk and missense ) were found elsewhere in therdxAcistron [ 73 ] .
Many other surveies have identified specific mutants inrdxAthat consequence in metronidazole opposition [ 71, 74-76 ] . The bulk of these mutants result in a abbreviated RdxA protein [ 77-79 ] . Other immune isolates have been identified that encode full length RdxA, but contain aminic acerb permutations ( Arg16His, Ala80Thr, Ala118Ser, Gln197Lys, Val204Ile [ 78 ] , Tyr46His, Pro51Leu, Ala67Val [ 77 ] , and Cys19Tyr [ 75 ] ) .
While inactivation ofrdxAclearly causes metronidazole opposition, the association of specific amino acerb mutants with opposition remains controversial, since really few surveies made specificrdxAamino acid permutations and so tested for opposition. Alternatively, immune strains are frequently identified, and sordxAis merely sequenced to place alterations and any differences are ascribed to leave metronidazole opposition, without separating resistance-associated nucleotide mutants from natural familial diverseness. However, newer surveies show that the bulk ofrdxAsequences were indistinguishable between susceptible and immune strains, taking the writers to propose that inactivation of RdxA is sufficient but non indispensable to obtain metronidazole opposition [ 76, 80 ] . This grounds, coupled with the fact that some immune strains do non hold mutants within therdxAcistron [ 74, 77, 81 ] , suggests that other opposition mechanisms exist inH. pylori.
Kwonet Al.were the first to detect that mutants in the NADPH flavin oxidoreductase cistron (frxA ) conferred metronidazole opposition [ 82 ] . Deletion mutants ensuing in shortnesss of thefrxAcistron confer metronidazole opposition [ 82, 83 ] , and missense mutants infrxA( Cys161Tyr, Arg206His, and a dual mutant of Trp137Arg and Glu164Gly ) , without specific alterations inrdxA,confer low degree opposition [ 83 ] . High metronidazole opposition is conferred when both thefrxAandrdxAcistrons are prematurely truncated, bespeaking a interactive consequence on opposition [ 75, 82, 83 ] . In contrast to these surveies, others have found thatfrxAinactivation does non significantly change susceptibleness to metronidazole [ 84 ] . Besides, The bulk of immune strains with mutants infrxAbesides have mutants inrdxA[ 85 ] , and shortnesss offrxAhave been identified in metronidazole sensitiveH. pyloriisolates [ 86 ] . These facts, combined with work that suggested that inactivation offrxAin a strain with a functionalrdxAmerely slowed the disinfectant effects of metronidazole [ 85 ] , has led some to propose that afrxAmutant entirely may non be plenty to leave opposition [ 87 ] .
Another contention in the metronidazole field lies in the argument as to whether other cistrons besidesrdxAandfrxAmay hold a function in metronidazole opposition. Some metronidazole immune isolates have functionalrdxAandfrxAwith no identified mutants, bespeaking that there are other mechanisms taking to metronidazole opposition [ 88 ] . One survey found that break of the nitroreductases,fdxB,resulted in metronidazole opposition [ 81 ] . Additionally, other reductases such as alkyl hydroperoxide reductase, AhpC [ 89 ] , have been suggested to play a function since the look degrees of assorted isoforms ofahpCare increased when immune strains are grown in the presence of metronidazole [ 90 ] . There is besides grounds that an efflux pump ( TolC ) is responsible for metronidazole opposition. When two of four TolC homologs ( HP0605 and HP0971 ) are mutated, it leads to an addition in susceptibleness to metronidazole even though single-knockout mutations are still immune [ 91 ] . Taken together, it is clear thatrdxAandfrxAmutants confer metronidazole opposition. However, the function of other cistrons and mutants require more thorough word picture.
Second Line Therapies and Resistance:
Tetracyclines are frequently used as a 2nd line therapy whenH. pyloriinfections are non cured by the first line drug regimen. The Achromycins include Achromycin, Aureomycin, Terramycin, Vibramycin, and tigilcycline [ 6 ] . Tetracyclines map by suppressing bacterial protein synthesis. They do this by adhering to the 30S ribosomal fractional monetary unit and barricading the fond regard of a new aminoacyl-tRNA to the ribosomal acceptor site [ 6, 92-94 ] . This efficaciously stops synthesis of bacterial peptides. However, since the interaction between the ribosome and the tetracyline is reversible, the antibiotic has a bacteriostatic consequence [ 92, 93 ] .
As with other drugs, opposition forms to Achromycins vary by geographic distribution: opposition rates are reasonably low ( 0-7 % in some countries ) [ 95, 96 ] , but higher in others ( every bit high as 59 % in China ) [ 97 ] . Tetracycline opposition inH. pyloriwas foremost observed in 1996 [ 98 ] , and chiefly occurs through change of bases within the primary Achromycin adhering site [ 99 ] . For case, a ternary mutant in the 16S rRNA cistron at bases 926-928, from AGA to TTC, has been shown to confabulate high degree tetraclycline opposition and is found worldwide [ 99-103 ] . Additionally, individual and dual mutants in this part weaken the interaction of 16S RNA with Achromycin, and consequence in moderate opposition to tetracycline [ 95, 102, 104, 105 ] .
While alterations in the 16S rRNA sequence are the primary mechanism of Achromycin opposition, there are studies of decrepit resistantH. pyloristrains with no mutants in their 16S rRNA [ 104, 105 ] . Furthermore, some of these Achromycin resistant strains demonstrate normal ribosome-tetracycline binding [ 104 ] . While the mechanism of oppositions in these strains is ill-defined, some possible accounts include the presence of efflux pumps or mutants in assorted porin cistrons [ 105 ] . Putative outflow systems have been identified inH. pylori[ 106 ] . Although no discernible Achromycin outflow activity was ab initio found [ 107 ] , a later survey found that the efflux pump, HefABC, really does demo efflux activity for Achromycin [ 45 ] . Additionally, mutants within this pump consequences in an addition in susceptibleness to tetracycline [ 45 ] .
Rescue/Salvage Therapy and Resistance:
Some of the newer arms used in the war againstH. pyloriare the fluoroquinolones. Fluoroquinolones include Cipro, gatifloxacin, sitafloxacin, monxifloxacin, temafloxacin, and levofloxacin. Presently, these drugs are used as deliverance or salvage therapy, when both first and 2nd line therapies have failed to eliminate infection. Fluoroquinolones mark toposoisomerase II ( gyrase ) or toposoisomerases IV ( a gyrase homologue ) activity of bacterial cells [ 108 ] . Bacterial gyrases act by doing cuts in DNA, therefore leting the nucleic acid strand to be in a relaxed orientation, where it is available for reproduction, recombination, and written text [ 6 ] . Resistance mutants to ciprofloxacin, in other bacterium has been found in aminic acids 67-106 of the gyraseA fractional monetary unit [ 109 ] . Therefore, this part has been deemed the “quinolone opposition finding part, ” or the QRDR [ 110 ] .
Fluorquinolone opposition rates vary geographically to every bit low as 13.8 % ( Lisbon ) [ 111 ] to between 21.5 % and 33.8 % ( depending on the fluoroquinolone ) in Korea [ 112 ] . As with other bacteriums, most quinolone opposition mutants inH. pyloriare found within the QRDR. The first amino acid mutants were Asn87Lys, Ala88Val, Asp91Gly, Asp91Asn, Asp91Tyr [ 112-114 ] , and a dual mutant at amino acid Asp91 to a Gly, Asn, or Tyr combined with either a Ala97Val or Ala97Asn permutation [ 112, 114 ] . The Ala97Val mutant has later been shown non to be associated with opposition when found entirely [ 115 ] . Other dual mutants identified as being of import in fluoroquinolone opposition are Ala84Pro/Ala88Val and Ser83Ala/Asn87Lys [ 114 ] . Miyachiet Al.found three new mutants doing levofloxacin opposition to be Asn87Ile, Asn87Tyr, and a dual mutant of Asn87His and Asp91Gly [ 116 ] . Indeed, many surveies have confirmed that the major mutant doing fluoroquinolone opposition occurs ingyrAat place 91 [ 112, 115, 117 ] or 87 [ 114, 116 ] : surveies have shown that 95.7 % of gatifloxacin immune strains [ 117 ] and 83.3 % of levofloxacin immune strains [ 116 ] contains mutants at these residues.
Presently, merely a individual resistant strain has been identified that does non incorporate a mutant within the QRDR [ 114 ] . This find suggests that there are extra mechanisms of fluoroquinolone opposition inH. pylori.Common mechanisms of opposition found in other bacteriums, such as efflux pumps and topoisomerase IV, appear non to use here, since there is grounds that outflow pumps are non a scheme for antimicrobic opposition to fluoroquinolones inH. pylori[ 45, 107 ] and cistrons such asparCorparEare non found in theH. pylorigenome [ 115, 118, 119 ] . Several surveies have besides looked atgyrB, but no mutants ensuing in opposition were isolated [ 115-117 ] . Therefore, presently the alternate mechanism of opposition remains unknown, and farther surveies need to be completed to hold a more inclusive apprehension of fluoroquinolone opposition.
Rifamycins, which consists of rifampicin and rifabutin, are used for deliverance therapy. These drugs are bacteriocidal, due to the irreversible obstruction of the DNA-dependent RNA polymerase [ 120 ] . While there are no prevalence surveies for opposition to rifamycins, opposition is possible by mutant within therpoBcistron, which encodes the ?-subunit of RNA polymerase [ 121 ] . Several different amino acids permutations have been shown to confabulate rifamycin opposition: Leu525Pro, Gln527Lys, Gln527Arg, Asp530Val, Asp530Asn, His540Tyr, His540Asn, Ser545Leu, Ile586Asn, and Ile586Leu [ 122 ] . Not surprisingly, these parts are besides of import for rifamycin opposition inE. coliand mycobacteriums [ 122 ] . Other aminic acids permutations withinrpoBthat have been shown to be of import for rifamycin opposition include Val149Phe [ 123, 124 ] and Arg701His [ 124 ] .
Nitrofurans are prodrugs that become active when the nitro group is reduced by an oxygen-insensitive nitroreductase. This activation consequences in the production of electrophilic intermediates that cause DNA harm and onslaught bacterial ribosomal proteins, therefore barricading protein synthesis and doing cell decease [ 125-127 ] . Nitrofurans consist of furazolidone and Macrodantin. Prevalence of nitrofuran opposition has been shown to be between 1.6 % [ 128 ] and 4 % [ 51 ] . This low opposition rate could be attributable to the fact that nitrofurans are non widely used.
While the mechanism of action of these drugs are similar to 5-nitroimidazoles, opposition is non acquired through the same mechanisms. While 5-nitroimidazole ( such as Flagyl ) opposition arises from mutants withinrdxAandfrxA, smashers of these cistrons did non bring forth opposition to furazolidone or nitrofurantoin [ 128 ] . This suggests that the nitrofurans could be used as an option to metronidazole [ 128 ] .
It has been suggested that activation of the nitrofurans requires two decrease stairss such as is the instance inE. coli[ 126, 128 ] . Evidence for two decrease stairss includes: the fact thatin vitroconsecutive transition does non bring forth any nitrofuran resistant strains [ 129 ] and that despite the fact that FrxA has the ability to cut down nitrofurans [ 130 ] , smashers offrxAmake non confabulate nitrofuran opposition [ 128 ] . Extra nitroreductases suggested as holding a function in ntirofuran opposition inH. pyloriare pyruvate: :flavodoxin oxidoreductase ( PorCDAB ) [ 128, 130 ] and 2-oxoglutarate oxidoreductase ( OorDABC ) [ 128 ] . When these cistrons are mutated, a low-level opposition is conferred to nitrofurans every bit good as to metronidazole [ 128 ] . If opposition is acquired in a two measure mechanism, these antibiotics may be the following good arm doctors have againstH. pylori.
Alternate interventions methods
Features ofH. pylori, such as high colonisation rates, length of service of infection, badness of associated diseases, and the ability to go immune to changing antibiotics with diverse mechanisms of action, has led to probe into alternate intervention methods. These options include modifying diet or vitamin consumption, developing a vaccinum forH. pylori,and modifying bing intervention governments. Alterations to diet or vitamin consumption includes the add-on of vitamin C addendums, which may cut down hazard of stomachic maladies [ 131-133 ] andH. pylori‘s ability to colonise [ 134, 135 ] , and prostaglandins ( either taken straight or obtained through polyunsaturated fatty acids ) , which protect the stomachic mucous membrane from harm [ 136-138 ] .
Arguably the best option would be the production of aH. pylorivaccinum, and several possible vaccinum campaigners are being researched [ 139-141 ] . Vaccine constituents vary and include killedH. pyloriwhole cell extracts [ 142 ] , heat daze proteins [ 143 ] , flagellar antigens [ 139 ] , adhesion antigens [ 144 ] , lipopolysaccaride antigens [ 145 ] , neutrophil triping protein [ 146 ] , and urease [ 147 ] . Unfortunately many of these are a long manner from human tests [ 139-141 ] , and the inactivated whole cell infusion were proven uneffective in a human voluntary survey [ 148 ] .
In stead of an affectional vaccinum, many new drugs have shown promise againstH. pylori. For case, other prodrugs use different primary reductases than Flagyl, supplying an alternate to a drug that is uneffective in many countries [ 130 ] . Newer fluoroquinolones ( sitafloxacin, HSR-903, gatifloxacin, Bay 12-8039, and trovafloxacin ) [ 149-151 ] and new rifamycins ( KRM-1657 and KRM-1648 ) [ 152 ] showin vitroactivity againstH. pyloriat low concentrations, proposing that they may be affectionalin vivo.
Alterations to current curative governments include the add-on of lactoferrin, which has been proven to better obliteration rates when used with certain ternary therapies [ 153 ] and lactobacillus, which has been proven to take down side effects of some antibiotics therefore, potentially increasing patient conformity [ 154, 155 ] . A concluding possible alteration to current curative governments is the add-on of a metal, such as Bi or Co II, to the intervention governments. Bismuth compounds prolong antibiotic usage by cut downing opposition rates every bit good as bring forthing a interactive consequence with several drugs [ 156, 157 ] . Cobalt II shows peculiar promise, as it is effectual at 100 times lower concentrations than Bi [ 158 ] .
H. pylorihas evolved into a extremely antimicrobic resistant pathogen, obtaining opposition to about all first, 2nd, and deliverance therapy antibiotics. Scientists have been able to place many of the molecular mechanisms that confer opposition ( Table 2 and Figure 1 ) . However, there are still some unknown opposition mechanisms to place. While presently it may look as ifH. pyloriis winning the war against antibiotics, hopefully new intervention options will better obliteration rate. Overall, it is clear that fresh schemes, such as inhibitors of virulency factors [ 159 ] , and drug development will be required to bring forth the tools to let doctors to yet win the war against this strategic pathogen.
Recognitions We would wish to thank Beth Carpenter for critical reading of the manuscript, Jeannette Whitmire for literature reappraisal and Jang Gi Cho for aid with Figure 1. Research in the research lab of D. Scott Merrell is supported by AI065529 from NIAID and R073LA from USUHS. The contents of this work are entirely the duty of the writers and do non needfully stand for the official positions of the NIH or DOD.
[ 1 ] The Study of Antibiotics as a Lesson in Scientific Methods. Am J Public Health Nations Health 1946 ; 36: 1310-3.
[ 2 ] Fleming A. On the antibacterial action of civilizations of a Penicillium, with particular mention to their usage in the isolation ofB. influenzae. Br J Exp Path 1929 ; tens: 3-13.
[ 3 ] Chain E, Florey H W, Gardner A D et Al. PENICILLIN AS A CHEMOTHERAPEUTIC AGENT. The Lancet 1940 ; 236: 226-8.
[ 4 ] Abraham E P, Chain E, Fletcher C M et Al. Further OBSERVATIONS ON PENICILLIN. The Lancet 1941 ; 238: 177-89.
[ 5 ] Bennett J W and Chung K T. Alexander Fleming and the find of penicillin. Adv Appl Microbiol 2001 ; 49: 163-84.
[ 6 ] Walsh C. Antibiotics: Actions, Origins, Resistance. Washington, DC, ASM Press. 2003.
[ 7 ] Marshall B J and Warren J R. Unidentified curved B in the tummy of patients with gastritis and peptic ulceration. Lancet 1984 ; 1: 1311-5.
[ 8 ] Blaser M J. Epidemiology and pathophysiology of Campylobacter pylori infections. Rev Infect Dis 1990 ; 12 Suppl 1: S99-106.
[ 9 ] Ernst P B and Gold B D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and stomachic malignant neoplastic disease. Annu Rev Microbiol 2000 ; 54: 615-40.
[ 10 ] Blaser M J. Helicobacter pylori and stomachic diseases. Bmj 1998 ; 316: 1507-10.
[ 11 ] Parsonnet J, Hansen S, Rodriguez L et Al. Helicobacter pylori infection and stomachic lymphoma. N Engl J Med 1994 ; 330: 1267-71.
[ 12 ] Blaser M J, Chyou P H and Nomura A. Age at constitution of Helicobacter pylori infection and stomachic carcinoma, stomachic ulcer, and duodenal ulcer hazard. Cancer Res 1995 ; 55: 562-5.
[ 13 ] Epidemiology of, and hazard factors for, Helicobacter pylori infection among 3194 symptomless topics in 17 populations. The EUROGAST Study Group. Gut 1993 ; 34: 1672-6.
[ 14 ] World Health Organization. Cancer Fact Sheet. hypertext transfer protocol: //www.who.int/mediacentre/factsheets/fs297/en/ . Accessed on 12/13/2007.
[ 15 ] Asaka M, Kudo M, Kato M, Sugiyama T and Takeda H. Review article: Long-run Helicobacter pylori infection — from gastritis to stomachic malignant neoplastic disease. Aliment Pharmacol Ther 1998 ; 12 Suppl 1: 9-15.
[ 16 ] Candelli M, Nista E C, Carloni E et Al. Treatment of H. pylori infection: a reappraisal. Curr Med Chem 2005 ; 12: 375-84.
[ 17 ] NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Jama 1994 ; 272: 65-9.
[ 18 ] Current European constructs in the direction of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997 ; 41: 8-13.
[ 19 ] Malfertheiner P, Megraud F, O’Morain C et Al. Current constructs in the direction of Helicobacter pylori infection — the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 ; 16: 167-80.
[ 20 ] Malfertheiner P, Megraud F, O’Morain C et Al. Current constructs in the direction of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 ; 56: 772-81.
[ 21 ] Cianci R, Montalto M, Pandolfi F, Gasbarrini G B and Cammarota G. Third-line deliverance therapy for Helicobacter pylori infection. World J Gastroenterol 2006 ; 12: 2313-9.
[ 22 ] Versalovic J, Shortridge D, Kibler K et Al. Mutants in 23S rRNA are associated with clarithromycin opposition in Helicobacter pylori. Antimicrob Agents Chemother 1996 ; 40: 477-80.
[ 23 ] Menninger J R. Functional effects of adhering macrolides to ribosomes. J Antimicrob Chemother 1985 ; 16 Suppl A: 23-34.
[ 24 ] Debets-Ossenkopp Y J, Sparrius M, Kusters J G, Kolkman J J and Vandenbroucke-Grauls C M. Mechanism of clarithromycin opposition in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 1996 ; 142: 37-42.
[ 25 ] Vester B and Garrett R A. A plasmid-coded and site-directed mutant in Escherichia coli 23S RNA that confers resistance to erythromycin: deductions for the mechanism of action of Erythrocin. Biochimie 1987 ; 69: 891-900.
[ 26 ] Nash K A and Inderlied C B. Familial footing of macrolide opposition in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995 ; 39: 2625-30.
[ 27 ] Taylor D E, Ge Z, Purych D, Lo T and Hiratsuka K. Cloning and sequence analysis of two transcripts of a 23S rRNA cistron from Helicobacter pylori and association of clarithromycin opposition with 23S rRNA mutants. Antimicrob Agents Chemother 1997 ; 41: 2621-8.
[ 28 ] Versalovic J, Osato M S, Spakovsky K et Al. Point mutants in the 23S rRNA cistron of Helicobacter pylori associated with different degrees of clarithromycin opposition. J Antimicrob Chemother 1997 ; 40: 283-6.
[ 29 ] Hulten K, Gibreel A, Skold O and Engstrand L. Macrolide opposition in Helicobacter pylori: mechanism and stableness in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 1997 ; 41: 2550-3.
[ 30 ] Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S and Munakata A. Clarithromycin-resistance and point mutants in the 23S rRNA cistron in Helicobacter pylori isolates from Japan. J Gastroenterol Hepatol 2000 ; 15: 906-9.
[ 31 ] Occhialini A, Urdaci M, Doucet-Populaire F, Bebear C M, Lamouliatte H and Megraud F. Macrolide opposition in Helicobacter pylori: rapid sensing of point mutants and checks of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997 ; 41: 2724-8.
[ 32 ] Wang G and Taylor D E. Site-specific mutants in the 23S rRNA cistron of Helicobacter pylori confer two types of opposition to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 1998 ; 42: 1952-8.
[ 33 ] Stone G G, Shortridge D, Flamm R K et Al. Designation of a 23S rRNA cistron mutant in clarithromycin-resistant Helicobacter pylori. Helicobacter 1996 ; 1: 227-8.
[ 34 ] Ribeiro M L, Vitiello L, Miranda M C et Al. Mutants in the 23S rRNA cistron are associated with clarithromycin opposition in Helicobacter pylori isolates in Brazil. Ann Clin Microbiol Antimicrob 2003 ; 2: 11.
[ 35 ] Raymond J, Burucoa C, Pietrini O et Al. Clarithromycin opposition in Helicobacter pylori strains isolated from Gallic kids: prevalence of the different mutants and coexistence of ringers harbouring two different mutants in the same biopsy. Helicobacter 2007 ; 12: 157-63.
[ 36 ] Alarcon T, Vega A E, Domingo D, Martinez M J and Lopez-Brea M. Clarithromycin opposition among Helicobacter pylori strains isolated from kids: prevalence and survey of mechanism of opposition by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 2003 ; 41: 486-99.
[ 37 ] Khan R, Nahar S, Sultana J, Ahmad M M and Rahman M. T2182C mutant in 23S rRNA is associated with clarithromycin opposition in Helicobacter pylori isolates obtained in Bangladesh. Antimicrob Agents Chemother 2004 ; 48: 3567-9.
[ 38 ] Toracchio S, Aceto G M, Mariani-Costantini R, Battista P and Marzio L. Identification of a fresh mutant impacting sphere V of the 23S rRNA cistron in Helicobacter pylori. Helicobacter 2004 ; 9: 396-9.
[ 39 ] Hao Q, Li Y, Zhang Z J, Liu Y and Gao H. New mutant points in 23S rRNA cistron associated with Helicobacter pylori opposition to clarithromycin in northeast China. World J Gastroenterol 2004 ; 10: 1075-7.
[ 40 ] Burucoa C, Landron C, Garnier M and Fauchere J L. T2182C mutant is non associated with clarithromycin opposition in Helicobacter pylori. Antimicrob Agents Chemother 2005 ; 49: 868 ; writer answer -70.
[ 41 ] Garrido L and Toledo H. Novel genotypes in Helicobacter pylori affecting sphere V of the 23S rRNA cistron. Helicobacter 2007 ; 12: 505-9.
[ 42 ] Fontana C, Favaro M, Minelli S et Al. New site of alteration of 23S rRNA associated with clarithromycin opposition of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother 2002 ; 46: 3765-9.
[ 43 ] Arthur M, Brisson-Noel A and Courvalin P. Origin and development of cistrons stipulating opposition to macrolide, lincosamide and streptogramin antibiotics: informations and hypotheses. J Antimicrob Chemother 1987 ; 20: 783-802.
[ 44 ] Meier A, Kirschner P, Springer B et Al. Designation of mutants in 23S rRNA cistron of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994 ; 38: 381-4.
[ 45 ] Kutschke A and de Jonge B L. Compound outflow in Helicobacter pylori. Antimicrob Agents Chemother 2005 ; 49: 3009-10.
[ 46 ] Paul T R, Halligan N G, Blaszczak L C, Parr T R, Jr. and Beveridge T J. A new mercury-penicillin V derived function as a investigation for ultrastructural localisation of penicillin-binding proteins in Escherichia coli. J Bacteriol 1992 ; 174: 4689-700.
[ 47 ] Georgopapadakou N H. Penicillin-binding proteins and bacterial opposition to beta-lactams. Antimicrob Agents Chemother 1993 ; 37: 2045-53.
[ 48 ] Blumberg P M and Strominger J L. Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol Rev 1974 ; 38: 291-335.
[ 49 ] new wave Zwet A A, Vandenbroucke-Grauls C M, Thijs J C, new wave der Wouden E J, Gerrits M M and Kusters J G. Stable Amoxil opposition in Helicobacter pylori. Lancet 1998 ; 352: 1595.
[ 50 ] Glupczynski Y, Megraud F, Lopez-Brea M and Andersen L P. European multicentre study of in vitro antimicrobic opposition in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001 ; 20: 820-3.
[ 51 ] Mendonca S, Ecclissato C, Sartori M S et Al. Prevalence of Helicobacter pylori opposition to metronidazole, clarithromycin, Amoxil, Achromycin, and furazolidone in Brazil. Helicobacter 2000 ; 5: 79-83.
[ 52 ] Rafeey M, Ghotaslou R, Nikvash S and Hafez A A. Primary opposition in Helicobacter pylori isolated in kids from Iran. J Infect Chemother 2007 ; 13: 291-5.
[ 53 ] Kalach N, Serhal L, Asmar E et Al. Helicobacter pylori primary resistant strains over 11 old ages in Gallic kids. Diagn Microbiol Infect Dis 2007 ; 59: 217-22.
[ 54 ] Godoy A P, Reis F C, Ferraz L F et Al. Differentially expressed cistrons in response to amoxicillin in Helicobacter pylori analyzed by RNA randomly primed PCR. FEMS Immunol Med Microbiol 2007 ; 50: 226-30.
[ 55 ] Dore M P, Graham D Y and Sepulveda A R. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 1999 ; 4: 154-61.
[ 56 ] Krishnamurthy P, Parlow M H, Schneider J et Al. Designation of a fresh penicillin-binding protein from Helicobacter pylori. J Bacteriol 1999 ; 181: 5107-10.
[ 57 ] Okamoto T, Yoshiyama H, Nakazawa T et Al. A alteration in PBP1 is involved in amoxicillin opposition of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2002 ; 50: 849-56.
[ 58 ] Gerrits M M, Schuijffel D, new wave Zwet A A, Kuipers E J, Vandenbroucke-Grauls C M and Kusters J G. Alterations in penicillin-binding protein 1A confer opposition to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002 ; 46: 2229-33.
[ 59 ] Kwon D H, Dore M P, Kim J J et Al. High-level beta-lactam opposition associated with acquired multidrug opposition in Helicobacter pylori. Antimicrob Agents Chemother 2003 ; 47: 2169-78.
[ 60 ] Co E M and Schiller N L. Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2006 ; 50: 4174-6.
[ 61 ] DeLoney C R and Schiller N L. Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 2000 ; 44: 3368-73.
[ 62 ] Harris A G, Hazell S L and Neting A G. Use of digoxigenin-labelled Principen in the designation of penicillin-binding proteins in Helicobacter pylori. J Antimicrob Chemother 2000 ; 45: 591-8.
[ 63 ] Rimbara E, Noguchi N, Kawai T and Sasatsu M. Correlation between permutations in penicillin-binding protein 1 and amoxicillin opposition in Helicobacter pylori. Microbiol Immunol 2007 ; 51: 939-44.
[ 64 ] Ings R M, McFadzean J A and Ormerod W E. The manner of action of Flagyl in Trichomonas vaginalis and other microorganisms. Biochem Pharmacol 1974 ; 23: 1421-9.
[ 65 ] O’Brien R W and Morris J G. Effect of Flagyl on H production by Clostridium acetobutylicum. Arch Mikrobiol 1972 ; 84: 225-33.
[ 66 ] Zullo A, Perna F, Hassan C et Al. Primary antibiotic opposition in Helicobacter pylori strains isolated in northern and cardinal Italy. Aliment Pharmacol Ther 2007 ; 25: 1429-34.
[ 67 ] Hu C T, Wu C C, Lin C Y et Al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 2007 ; 22: 720-3.
[ 68 ] Kumala W and Rani A. Patterns of Helicobacter pylori isolate opposition to fluoroquinolones, Amoxil, clarithromycin and Flagyls. Southeast Asiatic J Trop Med Public Health 2006 ; 37: 970-4.
[ 69 ] Moore R A, Beckthold B and Bryan L E. Metronidazole consumption in Helicobacter pylori. Can J Microbiol 1995 ; 41: 746-9.
[ 70 ] Chang K C, Ho S W, Yang J C and Wang J T. Isolation of a familial venue associated with metronidazole opposition in Helicobacter pylori. Biochem Biophys Res Commun 1997 ; 236: 785-8.
[ 71 ] Debets-Ossenkopp Y J, Pot R G, new wave Westerloo D J et Al. Interpolation of mini-IS605 and omission of next sequences in the nitroreductase ( rdxA ) cistron cause metronidazole opposition in Helicobacter pylori NCTC11637. Antimicrob Agents Chemother 1999 ; 43: 2657-62.
[ 72 ] Jorgensen M A, Manos J, Mendz G L and Hazell S L. The manner of action of Flagyl in Helicobacter pylori: ineffectual cycling or decrease? J Antimicrob Chemother 1998 ; 41: 67-75.
[ 73 ] Goodwin A, Kersulyte D, Sisson G, Veldhuyzen new wave Zanten S J, Berg D E and Hoffman P S. Metronidazole opposition in Helicobacter pylori is due to void mutants in a cistron ( rdxA ) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998 ; 28: 383-93.
[ 74 ] Tankovic J, Lamarque D, Delchier J C, Soussy C J, Labigne A and Jenks P J. Frequent association between change of the rdxA cistron and metronidazole opposition in French and North African isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000 ; 44: 608-13.
[ 75 ] Jorgensen M A, Trend M A, Hazell S L and Mendz G L. Potential engagement of several nitroreductases in metronidazole opposition in Helicobacter pylori. Arch Biochem Biophys 2001 ; 392: 180-91.
[ 76 ] Bereswill S, Krainick C, Stahler F, Herrmann L and Kist M. Analysis of the rdxA cistron in high-ranking metronidazole-resistant clinical isolates confirms a limited usage of rdxA mutants as a marker for anticipation of metronidazole opposition in Helicobacter pylori. FEMS Immunol Med Microbiol 2003 ; 36: 193-8.
[ 77 ] Jenks P J, Ferrero R L and Labigne A. The function of the rdxA cistron in the development of metronidazole opposition in Helicobacter pylori. J Antimicrob Chemother 1999 ; 43: 753-8.
[ 78 ] Kwon D H, Pena J A, Osato M S, Fox J G, Graham D Y and Versalovic J. Frameshift mutants in rdxA and metronidazole opposition in North American Helicobacter pylori isolates. J Antimicrob Chemother 2000 ; 46: 793-6.
[ 79 ] Solca N M, Bernasconi M V and Piffaretti J C. Mechanism of metronidazole opposition in Helicobacter pylori: comparing of the rdxA cistron sequences in 30 strains. Antimicrob Agents Chemother 2000 ; 44: 2207-10.
[ 80 ] Chisholm S A and Owen R J. Mutations in Helicobacter pylori rdxA cistron sequences may non lend to metronidazole opposition. J Antimicrob Chemother 2003 ; 51: 995-9.
[ 81 ] Kwon D H, El-Zaatari F A, Kato M et Al. Analysis of rdxA and engagement of extra cistrons encoding NAD ( P ) H flavin oxidoreductase ( FrxA ) and ferredoxin-like protein ( FdxB ) in metronidazole opposition of Helicobacter pylori. Antimicrob Agents Chemother 2000 ; 44: 2133-42.
[ 82 ] Kwon D H, Kato M, El-Zaatari F A, Osato M S and Graham D Y. Frame-shift mutants in NAD ( P ) H flavin oxidoreductase encoding cistron ( frxA ) from Flagyl immune Helicobacter pylori ATCC43504 and its engagement in metronidazole opposition. FEMS Microbiol Lett 2000 ; 188: 197-202.
[ 83 ] Kwon D H, Hulten K, Kato M et Al. Deoxyribonucleic acid sequence analysis of rdxA and frxA from 12 braces of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother 2001 ; 45: 2609-15.
[ 84 ] Jeong J Y and Berg D E. Mouse-colonizing Helicobacter pylori SS1 is remarkably susceptible to metronidazole due to two complementary reductase activities. Antimicrob Agents Chemother 2000 ; 44: 3127-32.
[ 85 ] Jeong J Y, Mukhopadhyay A K, Akada J K, Dailidiene D, Hoffman P S and Berg D E. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibleness and opposition to metronidazole. J Bacteriol 2001 ; 183: 5155-62.
[ 86 ] Yang Y J, Wu J J, Sheu B S, Kao A W and Huang A H. The rdxA cistron plays a more major function than frxA cistron mutant in high-ranking metronidazole opposition of Helicobacter pylori in Taiwan. Helicobacter 2004 ; 9: 400-7.
[ 87 ] Chisholm S A and Owen R J. Frameshift mutants in frxA occur often and make non supply a dependable marker for metronidazole opposition in UK isolates of Helicobacter pylori. J Med Microbiol 2004 ; 53: 135-40.
[ 88 ] Marais A, Bilardi C, Cantet F, Mendz G L and Megraud F. Characterization of the cistrons rdxA and frxA involved in metronidazole opposition in Helicobacter pylori. Res Microbiol 2003 ; 154: 137-44.
[ 89 ] Trend M A, Jorgensen M A, Hazell S L and Mendz G L. Oxidases and reductases are involved in metronidazole sensitiveness in Helicobacter pylori. Int J Biochem Cell Biol 2001 ; 33: 143-53.
[ 90 ] McAtee C P, Hoffman P S and Berg D E. Identification of differentially regulated proteins in metronidozole immune Helicobacter pylori by proteome techniques. Proteomicss 2001 ; 1: 516-21.
[ 91 ] new wave Amsterdam K, Bart A and van der Ende A. A Helicobacter pylori TolC efflux pump confers opposition to metronidazole. Antimicrob Agents Chemother 2005 ; 49: 1477-82.
[ 92 ] Chopra I and Roberts M. Tetracycline antibiotics: manner of action, applications, molecular biological science, and epidemiology of bacterial opposition. Microbiol Mol Biol Rev 2001 ; 65: 232-60 ; 2nd page, tabular array of contents.
[ 93 ] Chopra I, Hawkey P M and Hinton M. Tetracyclines, molecular and clinical facets. J Antimicrob Chemother 1992 ; 29: 245-77.
[ 94 ] Schnappinger D and Hillen W. Tetracyclines: antibiotic action, consumption, and opposition mechanisms. Arch Microbiol 1996 ; 165: 359-69.
[ 95 ] Lawson A J, Elviss N C and Owen R J. Real-time PCR sensing and frequence of 16S rDNA mutants associated with opposition and decreased susceptibleness to tetracycline in Helicobacter pylori from England and Wales. J Antimicrob Chemother 2005 ; 56: 282-6.
[ 96 ] Kwon D H, Kim J J, Lee M et Al. Isolation and word picture of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000 ; 44: 3203-5.
[ 97 ] Wu H, Shi X D, Wang H T and Liu J X. Resistance of helicobacter pylori to metronidazole, Achromycin and amoxycillin. J Antimicrob Chemother 2000 ; 46: 121-3.
[ 98 ] Midolo P D, Korman M G, Turnidge J D and Lambert J R. Helicobacter pylori opposition to tetracycline. Lancet 1996 ; 347: 1194-5.
[ 99 ] Gerrits M M, de Zoete M R, Arents N L, Kuipers E J and Kusters J G. 16S rRNA mutation-mediated Achromycin opposition in Helicobacter pylori. Antimicrob Agents Chemother 2002 ; 46: 2996-3000.
[ 100 ] Trieber C A and Taylor D E. Mutations in the 16S rRNA cistrons of Helicobacter pylori mediate opposition to tetracycline. J Bacteriol 2002 ; 184: 2131-40.
[ 101 ] Nonaka L, Connell S R and Taylor D E. 16S rRNA mutants that confer tetracycline opposition in Helicobacter pylori lessening drug binding in Escherichia coli ribosomes. J Bacteriol 2005 ; 187: 3708-12.
[ 102 ] Gerrits M M, Berning M, Van Vliet A H, Kuipers E J and Kusters J G. Effects of 16S rRNA cistron mutants on Achromycin opposition in Helicobacter pylori. Antimicrob Agents Chemother 2003 ; 47: 2984-6.
[ 103 ] Ribeiro M L, Gerrits M M, Benvengo Y H et Al. Detection of high-ranking Achromycin opposition in clinical isolates of Helicobacter pylori utilizing PCR-RFLP. FEMS Immunol Med Microbiol 2004 ; 40: 57-61.
[ 104 ] Wu J Y, Kim J J, Reddy R, Wang W M, Graham D Y and Kwon D H. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutants in 16S rRNA-encoding cistrons. Antimicrob Agents Chemother 2005 ; 49: 578-83.
[ 105 ] Dailidiene D, Bertoli M T, Miciuleviciene J et Al. Emergence of tetracycline opposition in Helicobacter pylori: multiple mutational alterations in 16S ribosomal DNA and other familial venue. Antimicrob Agents Chemother 2002 ; 46: 3940-6.
[ 106 ] Bina J E, Nano F and Hancock R E. Utilization of alkalic phosphatase mergers to place secreted proteins, including possible outflow proteins and virulency factors from Helicobacter pylori. FEMS Microbiol Lett 1997 ; 148: 63-8.
[ 107 ] Bina J E, Alm R A, Uria-Nickelsen M, Thomas S R, Trust T J and Hancock R E. Helicobacter pylori uptake and efflux: footing for intrinsic susceptibleness to antibiotics in vitro. Antimicrob Agents Chemother 2000 ; 44: 248-54.
[ 108 ] Smith J T. [ Mechanism of action of quinolones ] . Infection 1986 ; 14 Suppl 1: S3-15.
[ 109 ] Cullen M E, Wyke A W, Kuroda R and Fisher L M. Cloning and word picture of a DNA gyrase A cistron from Escherichia coli that confers clinical opposition to 4-quinolones. Antimicrob Agents Chemother 1989 ; 33: 886-94.
[ 110 ] Yoshida H, Bogaki M, Nakamura M and Nakamura S. Quinolone resistance-determining part in the DNA gyrase gyrA cistron of Escherichia coli. Antimicrob Agents Chemother 1990 ; 34: 1271-2.
[ 111 ] Cabrita J, Oleastro M, Matos R et Al. Features and tendencies in Helicobacter pylori antibiotic opposition in Lisbon country, Portugal ( 1990-1999 ) . J Antimicrob Chemother 2000 ; 46: 1029-31.
[ 112 ] Kim J M, Kim J S, Kim N, Jung H C and Song I S. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005 ; 56: 965-7.
[ 113 ] Wang G, Wilson T J, Jiang Q and Taylor D E. Spontaneous mutants that confer antibiotic opposition in Helicobacter pylori. Antimicrob Agents Chemother 2001 ; 45: 727-33.
[ 114 ] Moore R A, Beckthold B, Wong S, Kureishi A and Bryan L E. Nucleotide sequence of the gyrA cistron and word picture of ciprofloxacin-resistant mutations of Helicobacter pylori. Antimicrob Agents Chemother 1995 ; 39: 107-11.
[ 115 ] Tankovic J, Lascols C, Sculo Q, Petit J C and Soussy C J. Single and dual mutants in gyrA but non in gyrB are associated with low- and high-ranking fluoroquinolone opposition in Helicobacter pylori. Antimicrob Agents Chemother 2003 ; 47: 3942-4.
[ 116 ] Miyachi H, Miki I, Aoyama N et Al. Primary levofloxacin opposition and gyrA/B mutants among Helicobacter pylori in Japan. Helicobacter 2006 ; 11: 243-9.
[ 117 ] Nishizawa T, Suzuki H, Kurabayashi K et Al. Gatifloxacin opposition and mutants in gyra after unsuccessful Helicobacter pylori obliteration in Japan. Antimicrob Agents Chemother 2006 ; 50: 1538-40.
[ 118 ] Tomb J F, White O, Kerlavage A R et Al. The complete genome sequence of the stomachic pathogen Helicobacter pylori. Nature 1997 ; 388: 539-47.
[ 119 ] Alm R A, Ling L S, Moir D T et Al. Genomic-sequence comparing of two unrelated isolates of the human stomachic pathogen Helicobacter pylori. Nature 1999 ; 397: 176-80.
[ 120 ] Calvori C, Frontali L, Leoni L and Tecce G. Effect of rifamycin on protein synthesis. Nature 1965 ; 207: 417-8.
[ 121 ] Jin D J and Gross C A. Mapping and sequencing of mutants in the Escherichia coli rpoB cistron that lead to rifampicin opposition. J Mol Biol 1988 ; 202: 45-58.
[ 122 ] Heep M, Beck D, Bayerdorffer E and Lehn N. Rifampin and rifabutin opposition mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999 ; 43: 1497-9.
[ 123 ] Heep M, Rieger U, Beck D and Lehn N. Mutations in the beginning of the rpoB cistron can bring on opposition to rifamycins in both Helicobacter pylori and Mycobacterium TB. Antimicrob Agents Chemother 2000 ; 44: 1075-7.
[ 124 ] Heep M, Odenbreit S, Beck D et Al. Mutants at four distinguishable parts of the rpoB cistron can cut down the susceptibleness of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother 2000 ; 44: 1713-5.
[ 125 ] Jenks P J, Ferrero R L, Tankovic J, Thiberge J M and Labigne A. Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice. Antimicrob Agents Chemother 2000 ; 44: 2623-9.
[ 126 ] Whiteway J, Koziarz P, Veall J et Al. Oxygen-insensitive nitroreductases: analysis of the functions of nfsA and nfsB in development of opposition to 5-nitrofuran derived functions in Escherichia coli. J Bacteriol 1998 ; 180: 5529-39.
[ 127 ] McOsker C C and Fitzpatrick P M. Nitrofurantoin: mechanism of action and deductions for opposition development in common uropathogens. J Antimicrob Chemother 1994 ; 33 Suppl A: 23-30.
[ 128 ] Kwon D H, Lee M, Kim J J et Al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and function of cistrons involved in metronidazole opposition. Antimicrob Agents Chemother 2001 ; 45: 306-8.
[ 129 ] Haas C E, Nix D E and Schentag J J. In vitro choice of immune Helicobacter pylori. Antimicrob Agents Chemother 1990 ; 34: 1637-41.
[ 130 ] Sisson G, Goodwin A, Raudonikiene A et Al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and Flagyl in Helicobacter pylori. Antimicrob Agents Chemother 2002 ; 46: 2116-23.
[ 131 ] Block G, Patterson B and Subar A. Fruit, veggies, and malignant neoplastic disease bar: a reappraisal of the epidemiological grounds. Nutr Cancer 1992 ; 18: 1-29.
[ 132 ] Steinmetz K A and Potter J D. Vegetables, fruit, and malignant neoplastic disease. I. Epidemiology. Cancer Causes Control 1991 ; 2: 325-57.
[ 133 ] Zhang Z W, Patchett S E, Perrett D, Katelaris P H, Domizio P and Farthing M J. The relation between stomachic vitamin C concentrations, mucosal histology, and CagA seropositivity in the human tummy. Gut 1998 ; 43: 322-6.
[ 134 ] Wang X, Willen R and Wadstrom T. Astaxanthin-rich algal repast and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 2000 ; 44: 2452-7.
[ 135 ] Zhang H M, Wakisaka N, Maeda O and Yamamoto T. Vitamin C inhibits the growing of a bacterial hazard factor for stomachic carcinoma: Helicobacter pylori. Cancer 1997 ; 80: 1897-903.
[ 136 ] Johansson C, Aly A, Befrits R, Smedfors B and Uribe A. Protection of the gastroduodenal mucous membrane by prostaglandins. Scand J Gastroenterol Suppl 1985 ; 110: 41-8.
[ 137 ] Tarnawski A, Hollander D, Stachura J and Krause W J. Arachidonic acid protection of stomachic mucous membrane against alcohol hurt: consecutive analysis of morphologic and functional alterations. J Lab Clin Med 1983 ; 102: 340-51.
[ 138 ] Hollander D, Tarnawski A, Ivey K J et Al. Arachidonic acerb protection of rat stomachic mucous membrane against ethanol hurt. J Lab Clin Med 1982 ; 100: 296-308.
[ 139 ] Skene C, Young A, Every A and Sutton P. Helicobacter pylori scourge: antigenic profile and protective unsusceptibility. FEMS Immunol Med Microbiol 2007 ; 50: 249-56.
[ 140 ] Morihara F, Fujii R, Hifumi E, Nishizono A and Uda T. Effects of inoculation by a recombinant antigen ureB138 ( a section of the beta-subunit of urease ) against Helicobacter pylori infection. J Med Microbiol 2007 ; 56: 847-53.
[ 141 ] Zhao W, Wu W and Xu X. Oral inoculation with liposome-encapsulated recombinant merger peptide of urease B antigenic determinant and cholera toxin B fractional monetary unit affords contraceptive and curative effects against H. pylori infection in BALB/c mice. Vaccine 2007 ; 25: 7664-73.
[ 142 ] Raghavan S, Hjulstrom M, Holmgren J and Svennerholm A M. Protection against experimental Helicobacter pylori infection after immunisation with inactivated H. pylori whole-cell vaccinums. Infect Immun 2002 ; 70: 6383-8.
[ 143 ] Ferrero R L, Thiberge J M, Kansau I, Wuscher N, Huerre M and Labigne A. The GroES homolog of Helicobacter pylori confers protective unsusceptibility against mucosal infection in mice. Proc Natl Acad Sci U S A 1995 ; 92: 6499-503.
[ 144 ] Sutton P, Doidge C, Pinczower G et Al. Effectiveness of inoculation with recombinant HpaA from Helicobacter pylori is influenced by host familial background. FEMS Immunol Med Microbiol 2007 ; 50: 213-9.
[ 145 ] Fowler M, Thomas R J, Atherton J, Roberts I S and High N J. Galectin-3 binds to Helicobacter pylori O-antigen: it is upregulated and quickly secreted by stomachic epithelial cells in response to H. pylori adhesion. Cell Microbiol 2006 ; 8: 44-54.
[ 146 ] Satin B, Del Giudice G, Della Bianca V et Al. The neutrophil-activating protein ( HP-NAP ) of Helicobacter pylori is a protective antigen and a major virulency factor. J Exp Med 2000 ; 191: 1467-76.
[ 147 ] Begue R E, Cruz A R, Ramgoolam A and Breslin M B. Immunogenicity of Helicobacter pylori urease B protein and DNA vaccinums in a mouse theoretical account. J Pediatr Gastroenterol Nutr 2007 ; 45: 493-6.
[ 148 ] Kotloff K L, Sztein M B, Wasserman S S, Losonsky G A, DiLorenzo S C and Walker R I. Safety and immunogenicity of unwritten inactivated whole-cell Helicobacter pylori vaccinum with accessory among voluntaries with or without subclinical infection. Infect Immun 2001 ; 69: 3581-90.
[ 149 ] Sanchez J E, Saenz N G, Rincon M R, Martin I T, Sanchez E G and Martinez M J. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000 ; 46: 283-5.
[ 150 ] Takahashi Y, Masuda N, Otsuki M, Miki M and Nishino T. In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother 1997 ; 41: 1326-30.
[ 151 ] Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin ( AM 1155 ) , trovafloxacin, clinafloxacin, levofloxacin and Cipro. J Antimicrob Chemother 1997 ; 40: 639-51.
[ 152 ] Akada J K, Shirai M, Fujii K, Okita K and Nakazawa T. In vitro anti-Helicobacter pylori activities of new rifamycin derived functions, KRM-1648 and KRM-1657. Antimicrob Agents Chemother 1999 ; 43: 1072-6.
[ 153 ] Di Mario F, Aragona G, Bo N D et Al. Use of lactoferrin for Helicobacter pylori obliteration. Preliminary consequences. J Clin Gastroenterol 2003 ; 36: 396-8.
[ 154 ] Cremonini F, Di Caro S, Covino M et Al. Effect of different probiotic readyings on anti-helicobacter pylori therapy-related side effects: a parallel group, ternary blind, placebo-controlled survey. Am J Gastroenterol 2002 ; 97: 2744-9.
[ 155 ] Gotteland M, Brunser O and Cruchet S. Systematic reappraisal: are probiotics utile in commanding stomachic colonisation by Helicobacter pylori? Aliment Pharmacol Ther 2006 ; 23: 1077-86.
[ 156 ] Midolo P D, Lambert J R, Kerr T G and Tee W. In vitro synergism between Zantac Bi citrate and Achromycin or clarithromycin against immune strains of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1999 ; 18: 832-4.
[ 157 ] Van Caekenberghe D L and Breyssens J. In vitro interactive activity between Bi subcitrate and assorted antimicrobic agents against Campylobacter pyloridis ( C. pylori ) . Antimicrob Agents Chemother 1987 ; 31: 1429-30.
[ 158 ] Bruggraber S F, Gallic G, Th